Focus:

Cancer Center Featured Story 2

Add to Favorites Subscribe Share
fbshare-Cancer Center Featured Story 2

Showing results

110 of 1643
Newswise: Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer
  • Embargo expired:
    13-Dec-2019 11:30 AM EST

Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer

University of Texas M. D. Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center have identified a standardized protocol that uses image-guided breast biopsies to reliably predict residual disease in breast cancer patients and that potentially identifies exceptional responders who may not require surgery.

Channels: Cancer, Cell Biology, Women's Health, Medical Meetings,

Released:
10-Dec-2019 5:05 PM EST
logoMOFFITT_2c_RGB.jpg

The Rapid Tissue Donation Program at Moffitt Cancer Center Offers a Feasible Approach to Improve Research

Moffitt Cancer Center

In an article published in Cancer Medicine, Moffitt Cancer Center scientists describe a community-based program called the Rapid Tissue Donation (RTD) protocol. It enables patients to consent to donating tumor tissue and blood samples for research purposes after their death. The samples provided by patients postmortem enable researchers to study the genetic and molecular makeup of primary and metastatic tumors after the patient failed treatment, and to compare those finding with what was known about the patient during earlier phases of their therapy.

Channels: Cancer, Ethics and Research Methods, Healthcare, All Journal News,

Released:
13-Dec-2019 10:00 AM EST
Research Results
Newswise: Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival
  • Embargo expired:
    13-Dec-2019 8:30 AM EST

Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival

University of Texas M. D. Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes.

Channels: Cancer, Cell Biology, Women's Health, Medical Meetings,

Released:
10-Dec-2019 5:05 PM EST
Research Results
Newswise: Analysis of Different Treatment Strategies for Non-Invasive Breast Cancer Shows Radiation Treatment Alone is Cost-Effective

Analysis of Different Treatment Strategies for Non-Invasive Breast Cancer Shows Radiation Treatment Alone is Cost-Effective

Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey investigators evaluated all treatment strategies for both standard-risk and good-risk ductal carcinoma in-situ and found the most commonly recommended combination treatment for DCIS represents low-value care, while radiation therapy alone was cost-effective.

Channels: All Journal News, Cancer, Healthcare, Women's Health, Local - New Jersey, Medical Meetings,

Released:
11-Dec-2019 2:05 PM EST
Research Results
2018 NCCN Logo 2-Lines.jpg

Closing Gaps in Perspective of Value between Cancer Patients and their Health Care Providers

National Comprehensive Cancer Network® (NCCN®)

NCCN hosted an annual NCCN Patient Advocacy Summit: Delivering Value for Patients across the Oncology Ecosystem in Washington, DC, bringing together patients, advocates, clinicians, policy-makers, and others to share diverse perspectives on the meaning of value in cancer care.

Channels: Women's Health,

Released:
11-Dec-2019 2:00 PM EST
Research Results
Newswise: Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
  • Embargo expired:
    11-Dec-2019 9:45 AM EST

Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients

University of Texas M. D. Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.

Channels: Cancer, Cell Biology, Pharmaceuticals, Women's Health, Medical Meetings,

Released:
10-Dec-2019 5:05 PM EST
Policy
Newswise: A New Era of Care: The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center to Open in January 2020

A New Era of Care: The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center to Open in January 2020

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSK) today celebrated the opening of a $1.5 billion state-of-the-art cancer treatment facility with government officials, members of the Boards of Overseers and Managers, and staff. Opening for patient care next month, the 750,000-square-foot building is the institution’s — and the city’s — largest freestanding cancer care facility. The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center is a healing community dedicated to patient-centered care, made possible by a landmark donation and a pioneering vision that signifies a new era of cancer care.

Channels: All Journal News, Cancer, Healthcare, In the Workplace,

Released:
10-Dec-2019 3:55 PM EST
Research Results
Newswise: Yale Cancer Center researchers investigate inducing “synthetic lethality” in two blood and bone cancers

Yale Cancer Center researchers investigate inducing “synthetic lethality” in two blood and bone cancers

Yale Cancer Center

In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer

Channels: All Journal News, Blood, Cancer, Genetics, Healthcare, Medical Meetings,

Released:
10-Dec-2019 10:55 AM EST
Announcement
2018 NCCN Logo 2-Lines.jpg

NCCN Announces Projects Funded for Metastatic Breast Cancer Grant Program, in Collaboration with Pfizer

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces proposals selected for funding, in collaboration with Pfizer Global Medical Grants, to improve the quality of care and outcomes for people with metastatic breast cancer (MBC).

Channels: All Journal News, Cancer, Healthcare, Women's Health, Grant Funded News,

Released:
10-Dec-2019 8:35 AM EST
Research Results
Announcement

Showing results

110 of 1643

Chat now!
7.02246